Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ovid Therapeutics Inc (OVID)

Ovid Therapeutics Inc (OVID)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results GlobeNewswire - Tue May 12, 6:00AM CDT

Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteers OV329 showed favorable safety,...

OVID : 2.41 (-8.37%)
Ovid Therapeutics Reports Tomorrow With One Clinical Milestone Cleared and Another Still Unproven Barchart - Mon May 11, 4:06PM CDT

Barchart Research What to Expect from OVID Earnings OVID Generated May 11, 2026 Current Price $2.80 EPS Estimate $$-0.12 Consensus Rating Strong Buy Average Move 12.33% Ovid Therapeutics Reports Tomorrow...

OVID : 2.41 (-8.37%)
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14 GlobeNewswire - Wed Apr 8, 7:00AM CDT

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today...

OVID : 2.41 (-8.37%)
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire - Wed Mar 18, 5:05AM CDT

The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in focal...

OVID : 2.41 (-8.37%)
Ovid Therapeutics Announces Pricing of $60 Million Private Placement GlobeNewswire - Wed Mar 18, 5:00AM CDT

Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile spasms Financing led by Point72 with participation from...

OVID : 2.41 (-8.37%)
Ovid Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire - Wed Feb 25, 6:00AM CST

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by excess...

OVID : 2.41 (-8.37%)
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) GlobeNewswire - Thu Dec 18, 2025

OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071 There were no treatment-related laboratory findings,...

OVID : 2.41 (-8.37%)
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer GlobeNewswire - Tue Dec 2, 2025

NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today...

OVID : 2.41 (-8.37%)
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results GlobeNewswire - Wed Nov 12, 2025

Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of Directors Next-generation GABA-aminotransferase (GABA-AT)...

OVID : 2.41 (-8.37%)
B. Riley Securities Sticks to Their Buy Rating for Ovid Therapeutics (OVID) Tipranks - Fri Oct 10, 2025

B. Riley Securities analyst Madison Elsaadi maintained a Buy rating on Ovid Therapeutics today and set a price target of $5.00. The company’s shares closed today at $1.74.Elevate Your Investing Strategy:...

OVID : 2.41 (-8.37%)

Barchart Exclusives

A $3 Billion Reason to Buy Shell Stock Here (Plus It Has a Juicy 3.5% Dividend Yield) Barchart - Mon May 18, 6:30PM CDT
Shell recently announced a $3 billion stock buyback program. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.